Gene Therapy for Spinal Muscular Atrophy: Patient Perspective on Clinical Trials and Impact
Time: 2:35 pm
day: Day Two
• Impact of gene therapy on the SMA patient population
• What really matters? Existing unmet need. How does the risk/benefit ratio differ from developer to patient?
• Informing future gene therapy development and focusing on important metrics